Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15223383 | 0.90 | KMT2A (0.45) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL8722918 | 0.88 | KMT2A (0.53) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL6807835 | 0.88 | KMT2A (0.53) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL16128277 | 0.87 | CASP3 (0.50) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29800504 | 0.84 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29171843 | 0.84 | KMT2A (0.49) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL14948757 | 0.84 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29824019 | 0.83 | KMT2A (0.40) | KMT2AFABP5FABP7CASP3CA1 | |
| SCHEMBL29823660 | 0.83 | KMT2A (0.43) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL16128286 | 0.83 | FABP5 (0.48) | KMT2AFABP5FABP7CASP3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9695226-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-07-04 | — | — | US | disclosed |
| WO-2016077518-A1 | MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
| US-9221871-B2 | Methods for preparing internally constrained peptides and peptidomimetics | NEW YORK UNIVERSITY (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2014194030-A2 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| US-8865868-B2 | Conjugated proteins with prolonged in vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8779109-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-20140051828-A1 | METHODS FOR PREPARING INTERNALLY CONSTRAINED PEPTIDES AND PEPTIDOMIMETICS | NEW YORK UNIVERSITY | 2014-02-20 | — | — | US | disclosed |
| US-20140018290-A1 | LEPTIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2014-01-16 | — | — | US | disclosed |
| US-8071541-B2 | Methods for preparing internally constrained peptides and peptidomimetics | AILERON THERAPEUTICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051828-A1 | METHODS FOR PREPARING INTERNALLY CONSTRAINED PEPTIDES AND PEPTIDOMIMETICS | VIP, IAPP, PTMA | KMT2A 4780/4885FABP5 2654/4885FABP7 1619/4885 |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | KMT2A 3466/4885FABP5 396/4885FABP7 215/4885 |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | KMT2A 3466/4885FABP5 396/4885FABP7 215/4885 |
| US-20140018290-A1 | LEPTIN DERIVATIVES | FABP4, ADIPOR1, ADIPOR2 | KMT2A 4413/4885FABP5 77/4885FABP7 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.